Urea-based agents, such as PSMA-617 and PSMA-I&T (I&T indicating imaging and therapy) radiolabeled with lutetium-177 (177Lu) have been evaluated as therapy ligands for metastatic prostate cancer patients. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.